Effective Canadian policy to reduce harms from prescription opioids: learning from past failures

Affiliations

¹ Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (Fischer, Rehm); Department of Psychiatry (Fischer, Rehm), University of Toronto; Institute of Medical Science, Faculty of Medicine (Fischer, Rehm), University of Toronto; Dalla Lana School of Public Health (Rehm), University of Toronto, Toronto, Ont.; Department of Medicine (Tyndall), Faculty of Medicine, The University of British Columbia; BC Centre for Disease Control (Tyndall), Vancouver, BC benedikt.fischer@camh.ca.
² Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (Fischer, Rehm); Department of Psychiatry (Fischer, Rehm), University of Toronto; Institute of Medical Science, Faculty of Medicine (Fischer, Rehm), University of Toronto; Dalla Lana School of Public Health (Rehm), University of Toronto, Toronto, Ont.; Department of Medicine (Tyndall), Faculty of Medicine, The University of British Columbia; BC Centre for Disease Control (Tyndall), Vancouver, BC.

Benedikt Fischer et al. CMAJ. 2016.

. 2016 Dec 6;188(17-18):1240-1244.

doi: 10.1503/cmaj.160356. Epub 2016 Nov 7.

¹ Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (Fischer, Rehm); Department of Psychiatry (Fischer, Rehm), University of Toronto; Institute of Medical Science, Faculty of Medicine (Fischer, Rehm), University of Toronto; Dalla Lana School of Public Health (Rehm), University of Toronto, Toronto, Ont.; Department of Medicine (Tyndall), Faculty of Medicine, The University of British Columbia; BC Centre for Disease Control (Tyndall), Vancouver, BC benedikt.fischer@camh.ca.
² Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (Fischer, Rehm); Department of Psychiatry (Fischer, Rehm), University of Toronto; Institute of Medical Science, Faculty of Medicine (Fischer, Rehm), University of Toronto; Dalla Lana School of Public Health (Rehm), University of Toronto, Toronto, Ont.; Department of Medicine (Tyndall), Faculty of Medicine, The University of British Columbia; BC Centre for Disease Control (Tyndall), Vancouver, BC.

No abstract available

Comment in

An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders.
Socías ME, Ahamad K. Socías ME, et al. CMAJ. 2016 Dec 6;188(17-18):1208-1209. doi: 10.1503/cmaj.160554. Epub 2016 Nov 7. CMAJ. 2016. PMID: 27821463 Free PMC article. No abstract available.

1. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician 2012;15(Suppl):ES191–203. - PubMed
1. Fischer B, Rehm J, Patra J, et al. Changes in illicit opioid use profiles across Canada. CMAJ 2006;175:1385–7. - PMC - PubMed
1. Fischer B, Nakamura N, Rush B, et al. Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004–2009. Drug Alcohol Depend 2010;109:257–60. - PubMed
1. Murphy Y, Goldner EM, Fischer B. Prescription opioid use, harms and interventions in Canada: a review update of new developments and findings since 2010. Pain Physician 2015;18:E605–14. - PubMed
1. Fischer B, Kurdyak P, Goldner E, et al. Treatment of prescription opioid disorders in Canada: looking at the ‘other epidemic’? Subst Abuse Treat Prev Policy 2016;11:12. - PMC - PubMed